comms@paragonbiosci.com

60 items

May 26, 2026

JAMA Neurology Publishes Phase 3 Data on D1 Receptor Antagonist Ecopipam in Tourette Syndrome
Phase 3 data show delayed time to relapse [...]
April 29, 2026

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first‑in‑class selective dopamine D1 receptor [...]
March 6, 2026

First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy
Study opens pathway to investigational therapy for [...]
February 12, 2026

Biotech Innovation Update
Last year, Paragon Biosciences and [...]
February 28, 2025

Groundbreaking Achievements and Pivotal Milestones for Paragon and its Portfolio Companies
In 2024, Paragon and its [...]
February 27, 2025

Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
Topline data from Phase 3 study in [...]
November 19, 2024

Emalex Biosciences Named “Neuroscience Therapeutics Company Of The Year” by BioTech Breakthrough
Annual Awards Program Recognizes Innovation in the [...]
April 9, 2024

Article Highlights Positive Study Results Presented at AAN Annual Meeting
By Mary Beth Nierengarten, April 1, 2024 [...]